Exosomal Long Noncoding Rna AGAP2-AS1 Regulates Trastuzumab Resistance via Inducing Autophagy in Breast Cancer

Background: Trastuzumab has been widely used for treatment of HER-2-positive breast cancer patients, however, the clinical response has been restricted due to emergence of resistance. Recent studies indicate that long noncoding RNA AGAP2-AS1 (lncRNA AGAP2-AS1) plays an important role in cancer resistance. However, the precise regulatory function and therapeutic potential of AGAP2-AS1 in trastuzumab resistance is still not dened. Methods: Trastuzumab resistant cells were established. RNA sequencing and qRT-PCR were performed to identify the target gene of AGAP2-AS1. Mass spectrometry, RNA pulldown and RNA immunoprecipitation assays were performed to verify the direct interactions among AGAP2-AS1 and other associated targets, such as embryonic lethal abnormal version like RNA binding protein 1 (ELAVL1) and autophagy related 10 (ATG10). In vitro and in vivo experimental assays were done to clarify the functional role of exosomal AGAP2-AS1 in trastuzumab resistance. Results: AGAP2-AS1 promotes and disseminates trastuzumab resistance via packaging into exosomes. Exosomal AGAP2-AS1 induces trastuzumab resistance via modulating ATG10 expression and autophagy activity. Mechanically, AGAP2-AS1 is associated with ELAVL1 protein. The AGAP2-AS1-ELAVL1 complex could directly bind to the promoter region of ATG10, inducing H3K27ac and H3K4me3 enrichment, which nally activates ATG10 transcription. AGAP2-AS1-targeting antisenseoligonucleotides (ASO) substantially increased trastuzumab-induced cytotoxicity. Clinically, increased expression of serum exosomal AGAP2-AS1 was associate with poor response to trastuzumab treatment. Conclusion: ExosomalAGAP2-AS1 increased trastuzumab resistance via promoting ATG10 expression and inducing autophagy. Therefore, AGAP2-AS1 may serve aspredictive biomarker and therapeutic target for HER-2+ breast cancer patients.

Total RNA was isolated from the cultured cell lines or clinical samples by use of Trizolreagent (Invitrogen, Carlsbad, CA), and subjected to reverse transcription as requested(Takara, Shiga, Japan). The RNA concentration and purity were measured by Nanodrop 2000 (Thermo Scienti c, Waltham, MA, USA). The expression levels of mRNA and lncRNA were detected by the PrimeScript TM RT reagent kit (Takara, Dalian, China). qRT-PCR was carried out using the SYBR Premix Ex Taq TM (Takara, Dalian, China) andstandardized using GAPDH as reference gene.All reactions were carried out in triplicate. The relative expression was calculated using the 2 -△△ct method. PCR primers were listed in Additional le 1: Table S1.

Plasmid construction and cell transfection
For knockdown ofAGAP2-AS1 and ATG10, small interfering RNA (siRNA) was purchased from GenePharma (Shanghai, China). To construct a plasmid overexpressing AGAP2-AS1, the full-length human AGAP2-AS1 sequence was synthesized and subcloned into the pEX-3 vector (GenePharma, Shanghai, China). ThepENTER-ATG10 vector used for overexpression ofATG10 mRNA was provided by Vigene BioSciences, followed by transfection into BC cells using Lipofectamine 2000 for 48 h (Invitrogen). For stably overexpressing or silencing AGAP2-AS1, we constructed lentivirus-based vectors from Genechem (Shanghai, China). The sequences of oligonucleotides are presented in Additional le 1: Table S1.

CCK8 assay
The cells transfected accordingly were seeded in a 96-well plate, the cells were cultured for 72 h with different dose of trastuzumab. After that, 10 mg/mL of CCK8 reagent (Dojindo, Kumamoto, Japan) was supplemented for cell viability detection according to manufacturer's protocols. The absorbance at 450 nm was measured with a microplate reader. The dose for the half survival was represented the halfmaximal inhibitory concentration (IC50) of trastuzumab in SKBR-3-TR and BT474-TR cells.
Then, 63µl ExoQuick TM exosome precipitation solution (SBI, USA) was added into 250µl serum followed by incubation at 4℃ for 50 min. After centrifugation at 1500 g for 30 minutes, exosomes were collected. 50µl phosphate-buffered saline (PBS) was used to resuspend the exosome pellets obtained from the former step. Exosome isolated from serum of BC patients were done with similar procedures.
The sample of exosomes was identi ed through transmission electron microscopy, nanoparticle tracking analysis (NTA, Malvern Panalytical). Exosomes were loaded on a Formvar-carbon-coated electron microscope grid(Polysciences) for 30 min. Then the grid was washed in PBS and xed in 2% glutaraldehyde(Sigma Aldrich) for 10 min. The grid was subsequently washed in PBS for 5 times andcounter-stained with 2% uranyl acetate (Sigma Aldrich) for 1 min. Air-dried grids wereviewed with a Hitachi transmission electron microscope.

RNA sequencing analysis
Total RNA was extracted from wild type or AGAP2-AS1-knock out SKBR-3 cells using RNeasy mini kit (Qiagen, Germany). The paired-end libraries were constructed by using TruSeq™ RNA Sample Preparation Kit (Illumina, USA) according to the manufacture'ssample preparation guide. The mRNA expression pro les of the treated cells were determined using the Illumina NovaSeq 6000 (Illumina, USA) following the manufacturer's instructions. The library construction and sequencing were performed at Shanghai Sinomics Corporation (Shanghai, China).Cuffdiff was used to evaluate differentially expressed genes. The differentially expressed genes were selected using the following lter criteria: P≤0.05 and fold change ≥2.
Subcutaneous tumorigenicity assay 4-week-old female BALB/c nude mice were purchased from the Beijing Vital River Laboratory Animal Technology and housed in speci c pathogen-free barrier facilities. Fifteen mice were randomly assigned to two exosome-treated groups and one control group (5 mice/group). Mice were subcutaneous injected SKBR-3-TR cells (1×10 6 cells in 0.1ml physiological saline) in the ank. Each group received PBS, SKBR-3-TR-EXO Vector , or SKBR-3-TR-EXO AGAP2-AS1 treatmentsevery 3 days for 5 weeks. Meanwhile, each group received intraperitoneal treatment of trastuzumab once every two days for 4 weeks. After 4 weeks postinjection, mice were imaged using a luminescence imaging system. At the end of imaging, all mice were euthanized by carbon dioxide inhalation, followed by cervical dislocation to ensure death. Then, tumors were surgically dissected and weighted. Tumor volume (mm 3 ) = 0.5 × width 2 × length.
To test the therapeutic role of AGAP2-AS1, ASO was used for treatment of xenograft tumors through tail vein injection. Brie y, 5×10 5 SKBR-3-TR cells in 100μL of sterile PBS were injected directly into the mammary fat pads of mice to establish in situ xenograft. Then, mice were divided into 3 groups (n =5 in each group) after the xenograft was established. ASO was used at the concentration of 10 nmol, twice a week.
All experimental procedures were conducted in conformity with the ethical standards of national and international guidelines and policies. This study was approved by the Institute Animal Care and Use Committee of The First A liated Hospital of Zhengzhou University (Zhengzhou, China).
RNA pulldown AGAP2-AS1 was transcribed using T7 RNA polymerase in vitro (Ambio Life) followed by the puri cation with RNeasy Plus Mini Kit (Qiagen) treatment with DNase I (Qiagen). The cell lysates were freshly prepared using Magnetic RNA-Protein Pull-Down Kit (Thermo Fisher Scienti c, Cat# 20164). Cell protein extracts were collected and mixed with the biotinylated RNA probes for AGAP2-AS1 in magnetic beads. Resultswere analyzed by sliver staining and mass spectrometry (ekspertTMnanoLC; AB Sciex TripleTOF 5600-plus; SCIEX). Data were analyzed using Proteinpilot software (https://omictools.com/proteinpilot-tool). The retrieved protein ELAVL1 was further validated by standard western blot.

RNA immunoprecipitation (RIP) and Chromatin immunoprecipitation (ChIP)
Using EZ-Magna RIP RNA Binding Protein Immunoprecipitation Kit,RIP assay was implemented as instructed by supplier (Millipore, Billerica,MA). Cell lysates were reaped for incubation with the ELAVL1 (cat. no. ab200342, Abcam, Cambridge, MA) antibody in magnetic beads, using IgG antibody as negativecontrol. All precipitates wereexamined by qRT-PCR.
For ChIP assay, the Millipore EZ ChIP Kit (Millipre) was used according to the manufacture's guideline. After xation with 4%formaldehyde, cells were lysed by using RIPA buffer (Beyotime, Shanghai, China).

RNA uorescent in situ hybridization (RNA-FISH)
The colocalization of AGAP2-AS1 and ELAVL1 were con rmed by uorescence staining. Brie y, SKBR-3 cells were seeded on a glass-bottomed confocal plate and cultured overnight. After xation with 4% PFA and permeabilization with 0.5% Triton, hybridization was carried out overnight with the AGAP2-AS1 probes conjugated with Alexa Fluor 555 (Invitrogen, CA,USA) at 37°C in 2×SSC, 10% formamide and 10% dextran. Subsequently, Anti-ELAVL1 was incubated in the dark overnight followed by incubation with secondary antibody for 1h. Finally, the nuclei were stained by DAPI and the images were captured under a Nikon A1Si Laser Scanning Confocal Microscope (Nikon Instruments Inc, Japan).

Immunohistochemistry (IHC) analysis
For IHC, the formalin-xed, para n-embedded sections were dewaxed and rehydrated aspreviously described [17], and then treated with 3% hydrogen peroxide followed by EDTA buffer for antigenretrieval.
The sections were then blocked in goat serum for 30 min, incubated with rabbit anti ATG10 antibody (Abcam, cat. no. ab229728) at 4°C overnight and subsequent with horseradish peroxidaseconjugatedsecondary antibodies for 30 min at room temperature. Finally, the sections were stained withthe DAB substrate and hematoxylin. Images were recorded by Nikon Eclipse Ti microscope.

Western Blot analysis
Protein extraction were performed using RIPA lysis buffer (Pierce, IL, USA) containingprotease inhibitor (Roche, CA, USA). Protein extracts were subjected to 10%SDS-polyacrylamide gel electrophoresis followed by electro-transfer to polyvinylidenedi uoride membrane. After 1h of pre-membrane blocking with 5% BSA, the proteins wereincubated with respective primary antibodies at 4°C overnight followed by secondaryantibodies incubation at room temperature for 1 h. The detection of proteins was carried outusing ECL reagent.

Statistical analysis
Each experiment contained at least 3 individual bio-replications. Datawere all given as the mean ± standard deviation (SD) and processed withPrism Version 5.0 (GraphPad Software, La Jolla, CA). Statistical analysisin form of Student's t-test or one-way analysis of variance (ANOVA),was considered to be signi cant when p-values below 0.05.

Results
AGAP2-AS1 was enriched in BC cell-secreted exosomes Previously, we identi ed an upregulation of AGAP2-AS1 in trastuzumab-resistant BC cells compared to parental cells [17]. However, whether AGAP2-AS1 can be packaged into extracellular materials, such as exosome, is not well known. By using SKBR-3-TR cells, we extracted exosomes from thecell culture medium and con rmed by transmission electron microscopy (TEM) (Fig. 1A) and NanoSight analysis (Fig. 1B). The exosomes were further con rmed by western blotting analysis of exosomal markers, TSG101 and HSP70 (Fig. 1C). qRT-PCR indicated that the expression of AGAP2-AS1 packaged in exosome was signi cantly increased in trastuzumab-resistant cells in contrast to the respective parental cells (Fig. 1D). Moreover, AGAP2-AS1 was more enriched in exosomes in contrast to intracellular portions, indicating that AGAP2-AS1 may function via incorporating into exosomes (Fig. 1E). Importantly, knockdown of cellular AGAP2-AS1 via transfection of AGAP2-AS1 small interfere vectors induced a dramatically decrease of exosomal AGAP2-AS1 expression ( Fig. 1F and 1G), while overexpression of cellular AGAP2-AS1 showed opposite effects ( Fig. 1H and 1I), strengthening our conclusion that AGAP2-AS1 was enriched in extracellular exosomes.
To provide direct evidence that exosomal AGAP2-AS1 was internalized by BC cells, we labeled extracted exosomes with PKH67 green dye. As expected, a strong green uorescence signal was observed in recipient cells while no signal was observed in PBS control group (Fig. 2D). To eliminate the possibility that endogenous AGAP2-AS1 induced trastuzumab resistance of BC parental cells. We built AGAP2-AS1knockout SKBR-3 and BT474 cells from using the CRISPR-Cas9 approach with double-strained sgRNAs targetingAGAP2-AS1. A successful de ciency of AGAP2-AS1 was con rmed by our qRT-PCR analysis (Fig. 2E). CCK8 assay proved that AGAP2-AS1-overexpressed cell-secreted exosomes promoted trastuzumab resistance of AGAP2-AS1-knockout cells (Fig. 2F). These results were consistent with that of AGAP2-AS1-wild type BC cells (Fig. 2G). Taken together, we demonstrated that AGAP2-AS1overexpression cells could spread trastuzumab resistance by transferring exosomal AGAP2-AS1 to sensitive cells.

Exosomal AGAP2-AS1 promotes trastuzumab resistance via inducing autophagy
It is well demonstrated that autophagy may decrease the cytotoxicity ofdrugsupon cancer cells, inducing resistance [20]. Interestingly, the Gene Ontology (GO) analysis showed that autophagy may be involved in the function of AGAP2-AS1 (Fig. 3A). To nd whether AGAP2-AS1 regulates trastuzumab resistance via inducing autophagy, we rstly measured the autophagy activity of BC cells. Remarkably, compared to BC parental cells, trastuzumab-resistant cells showed higher activity of autophagy, as evidenced by increased expression of LC3-II, decreasedexpression of p62 protein and increased formation of LC3 puncta, than the corresponding parental cells, con rming the close association between autophagy and drug resistance in cancer ( Fig. 3B-C). To identify the direct role of autophagy in trastuzumab resistance, we used chloroquine (CQ), a well-known autophagy inhibitor [21]. As expected, CQ treatment inhibited autophagy activity and deteriorated trastuzumab resistance ( Fig. 3D-E).

Exosomal AGAP2-AS1 upregulates ATG10 expression to induce trastuzumab resistance in vitro
To clarify the functional target of AGAP2-AS1 in autophagy and trastuzumab resistance, we performed RNA sequencing with AGAP2-AS1 knockout SKBR-3 cellsandwild-type controlled cells. Preliminarily, 1247 genes were identi ed with statistical signi cance (Fold change > 2) in both cell lines (Fig. 4A). Given the fact that AGAP2-AS1 may in uence trastuzumab resistance via regulating autophagy, we focus on 27 autophagy-related genes, including ATG10 and ATG5 (Fig. 4B). By performing qRT-PCR, we identi ed ve genes were signi cantly altered upon silence of AGAP2-AS1 in trastuzumab resistant cells (Fig. 4C). Western blotting showed that the protein levels of two of those genes, ATG10 and ATG5 were silenced by AGAP2-AS1 knockdown (Fig. 4D). Moreover, ATG10 was upregulated in trastuzumabresistant cells compared to parental cells in both transcript and protein levels (Fig. 4E), whereas ATG5 was not altered (data not shown). Functionally, knockdown of ATG10 signi cantly reversed the AGAP2-AS1-induced autophagy activity and trastuzumab resistance ( Fig. 4F and G), while silence of ATG5 showed no effect (data not shown), suggesting that ATG10 may be directly targeted by AGAP2-AS1 and mediates the AGAP2-AS1-induced autophagy and trastuzumab resistance.
It is reported that ELAVL1 play a role in stabilizing mRNAs by binding AU-rich elements (AREs) [23]. To verify whether ELAVL1 stabilized AGAP2-AS1, we silenced ELAVL1 expression in BC cells (Fig. 6J). Silence of ELAVL1 caused downregulation of AGAP2-AS1 in trastuzumab resistant cells (Fig. 6K). Importantly, when we blocked RNA transcription process by using actinomycin D (ActD), the stability of AGAP2-AS1 RNA wasdramatically suppressed in ELAVL1-silenced cells compared to that in control cells (Fig. 6L). Our results indicate that ELAVL1 directly binds to AGAP2-AS1 and maintain its stability.
To further con rm AGAP2-AS-ELAVL1 interacted with ATG10 promoter to induce histone modi cation, we evaluated the role of AGAP2-AS1 and ELAVL1 in H3K27me3 and H3K27ac enrichment. Fig. 7D showed that knockdown of AGAP2-AS1 decreased H3K27me3 and H3K27ac enrichment in SKBR-3-TR and BT474-TR cells. Enrichment of the ATG10 promoter sequences associated with H3K4me3 and H3K27ac were increased in SKBR-3 and BT474 cells incubated with exosomes secreted by AGAP2-AS1-transfected SKBR-3-TR cells (Fig. 7E). Interestingly, the effect caused by ectopic expression of AGAP2-AS1 was signi cantly reversed in cells silenced with ELAVL1, indicating that ELAVL1 is essential for AGAP2-AS1induced transcription activation (Fig. 7F). Although ELAVL1 could participate in the regulation of RNA stability, ActD treatment showed that ELAVL1 had little effect on half-life of ATG10 mRNA (data not shown).
Targeting AGAP2-AS1 with ASO showed potential inreversing trastuzumab resistance Various in vitro, in vivo and pre-clinical studies proved that antisense oligonucleotide (ASO) may serving as promising small molecular drugs by generating speci c vectors against diverse RNAs [24]. To investigate the potential of ASOs targeting AGAP2-AS1 in overcoming trastuzumab resistance, three ASOs against AGAP2-AS1 and one negative control were designed (Fig. 8A). AGAP2-AS1 was silenced by ASO-1 and ASO-2 in trastuzumab resistant BC cells (Fig. 8B). Cell suppression induced by trastuzumab was promoted by ASO-interfered AGAP2-AS1 (Fig. 8C-D). ATG10 expression and autophagy activity were also suppressed when AGAP2-AS1 was silenced (Fig. 8E). By optimizing the ASOs, we tested their functional e ciency in vivo. Free uptake assay revealed that two ASOs inhibited AGAP2-AS1 expression compared to negative control in SKBR-3-TR cells in adose-dependent manner (Fig. 8F). SKBR-3-TR cells were planted into mammary fat pads. When orthotopic xenograft tumor was established, mice were separated into 3 groups and injected via tail vein with ASO-1, ASO-2 or negative control ASO twice a week for 4 weeks (Fig. 8G). Meanwhile, each group received intraperitoneal treatment of trastuzumab. Tumor growth was signi cantly suppressed in two ASO-treated groups compared to ASO-control group, suggesting that trastuzumab combined with AGAP2-AS1 knockdown via ASO could induce better anticancer effects, when compared to trastuzumab treatment only (Fig. 8H). ATG10 expression was also suppressed in tissues treated with the two ASOs compared to control group (Fig. 8I). Taken together, our results indicate that targeting AGAP2-AS1 with ASOcombing drugs might be a promising therapeutic approach to overcome trastuzumab resistance.
Circulating exosomal AGAP2-AS1 predicts response to trastuzumab treatment of BC patients To determine the predictive value of exosomal AGAP2-AS1 in trastuzumab response of BC patients, we analyzed its expression in 90 serum samples from patients receiving trastuzumab treatment (45 responding and 45 non-responding patients). As shown in Fig. 9A, exosomal AGAP2-AS1 is upregulated in nonresponding patients compared to responding patients. Moreover, receiver operator characteristic (ROC) curve showed a relatively high predictive value of exosomal AGAP2-AS1 in discriminating responding and non-responding patients, with an area under the curve (AUC) at 0.784, and diagnostic sensitivity and speci city at 77.8% and 73.3%, respectively (Fig. 9B). By stratifying patients into a high or low exosomal AGAP2-AS1 expression group with a strati cation criteria (4.06) obtained from the ROC curve, we found that the percent of patients showing response to trastuzumab therapy was much lower in high AGAP2-AS1-expressed group than that fromlow AGAP2-AS1-expressed group (Fig. 9C), further strengthening the predictive value of exosomal AGAP2-AS1 in discriminating responding and nonresponding patients.

Discussion
Despite current chemotherapeutic regimens that evidently improved the survival of metastatic tumors, nearly all HER-2+ BC patients nally develop into resistance [25,26].LncRNAs are dysregulated invarious cancers, and modulates drug resistance byinteracting with RNA and proteins [27]. Until now, the precise regulatory mechanisms by which lncRNAs regulate trastuzumab resistance in BC is still not clearlyde ned. In this study, we investigated the pivotal role and post-transcriptional regulation of lncRNA AGAP2-AS1 in trastuzumab resistance. We revealed that AGAP2-AS1 promotes trastuzumab resistance via packaging into exosomes. In addition, AGAP2-AS1 directly interacted with ELAVL1 which in turn stabilizes AGAP2-AS1; the AGAP2-AS1-ELAVL1 complex could directly bind to promoter of ATG10, inducing an enhanced transcriptional activity of ATG10through increasing H3K4me3 and H3K27acenrichment, and nally lead to the activation autophagy and trastuzumab resistance (Fig. 9D).
During recent years, more useful therapeutic methods were developed for the treatment of HER-2+ breast cancer [28], however, trastuzumab resistance still occurs and dramatically reduced the clinical practicality and response, which has become one of the most urgent challenges for promoting breast cancer outcome. Furthermore, lacking of effective prognostic biomarkers that could be used for predicting therapeutic response to trastuzumab also greatly hindered the improvement of HER-2 positive patients [29]. In addition to the molecular alterations discussed above, there is increased expression of a number of RTKs-IGF-1Rβ, c-Met, and EGFR-that are implicated in trastuzumab resistance [30]. Currently, very limited biomarkers are useful in guiding therapeutic decisions among HER-2+ patients except for HER-2 itself [31]. Hence, more and more studies needs to be devote to nding promising therapeutic targets and prognostic biomarkers[32, 33].
In recent years, the functions of lncRNAs have drawn more and more attention. A great number of studies have indicated that lncRNAs play important roles in all steps of carcinogenesis and tumor progression, and lncRNAs could be used as new prognostic markers [34,35]. More recently, emerging evidence has indicated that exosomes regulate malignancyby transferring multiple classes of cargo molecules to recipient cells to mediateintercellular communication, including lncRNAs. Exosomal lncRNAs participate in tumor formation,proliferation, metastasis and chemotherapy resistance by regulating oncogenes ortumor suppressor genes [9,36,37]. However, communication in BC cells withdifferent drug response via exosomes is obscured. In this study, we proved that AGAP2-AS1 lncRNA could be incorporated into exosomes and further internalized by recipient cells to transmit resistant property.
Autophagy can be a double-edged sword for resistant tumors: it participates in the development of drug resistance and protects cancer cells from chemotherapeutics but can also kill cancer cells in which apoptosis pathways are inactive. Therefore, research on the regulation of autophagy to combat resistance is expanding and is becoming increasingly important[38]. By screening potential targeted mRNAs, we identi ed ATG10 as one potentially regulated by AGAP2-AS1 and may play pivotal roles in trastuzumab resistance via regulating autophagy. Further experimental data proved that ATG10 expression is positively regulated by AGAP2-AS1 and essential for AGAP2-AS1-induced autophagy and trastuzumab resistance. ATG10 is an autophagic E2-like enzyme that interacts with ATG7 to recruit Our results suggest that there exists a direct interaction between AGAP2-AS1 and ELAVL1 protein, and the binding of AGAP2-AS1 by ELAVL1 increased the stability of AGAP2-AS1. In addition, AGAP2-AS1-ELAVL1 complex further binds to the promoter of ATG10, altering histone modi cations and activating transcription. Moreover, the AGAP2-AS1-induced formation of H3K27ac and H3K4me3 was abolished by knockdown of ELAVL1, suggesting that ELAVL1 is essential for this epigenetic regulation. Reciprocally, overexpression of ELAVL1 only partlyreversed thedecrease of H3K4me3 and H3K27ac enrichment inAGAP2-AS1 silencing cells, indicating thatthe enhanced transcriptional activity at ATG10 promoter is dependent on the histone modi cation induced by AGAP2-AS1-ELAVL1 complex.
We need to point out two limitations of our study. First, we explored the experimental role of ASO targeting AGAP2-AS1 in reversing trastuzumab resistance, however, this may need further validation in clinical trials. Second, we preliminarily con rmed the function of AGAP2-AS1/ELAVL1/ATG10 in autophagy and trastuzumab resistance, however the precise regulatory model, and the ongoing interactions with other cellular factors in tumor microenvironment during this process need more meaningful studies.

Conclusions
In summary, we demonstrated the crucial role of AGAP2-AS1 in trastuzumab resistance of BC by epigenetically increasing ATG10 expression and thereby promoting autophagy. Our discovery not only help us get a better understanding the regulatory potential of AGAP2-AS1 in drug resistance of HER-2+ BC, but alsouseful for nding promising drug targets and developing novel therapeutic strategiesto overcome resistance.

Consent for publication
Not applicable.

Availability of data and material
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests
The authors declare that they have no competing interests.

Funding
This study is supported by National Science Foundation of China (81960475) and The "Nanhai series" talent cultivation program of Hainan Province.  AGAP2-AS1 was interacted and stabilized by ELAVL1 (A) Silver-stained RNA pulldown assay usingbiotinylated AGAP2-AS1and sense control were performed, and a speci c band was identi ed. (B) Mass spectrometry analysis of proteins from RNA pulldown, and the ELAVL1 atlas was shown. (C-D) Western blotting con rmed the interacted protein was ELAVL1. (E) RNA-FISH with speci c probe veri ed that AGAP2-AS1 and ELAVL1 colocalized mostly in the cytoplasm of SKBR-3 cells. (F) RIP assay with ELAVL1 protein further con rmed the direct interaction between AGAP2-AS1 and ELAVL1. (G) Serial